HC Wainwright & Co. Reiterates Buy on Tourmaline Bio, Maintains $48 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Tourmaline Bio (NASDAQ:TRML) and maintained a $48 price target on the stock.
March 20, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Tourmaline Bio, with a $48 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a $48 price target by a reputable analyst suggests a strong confidence in Tourmaline Bio's future performance. This endorsement is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100